Novartis Trying to Buy Israeli Stem Cell Research Developer – The Jewish Press
| The Jewish Press Gamida Cell has proprietary technology for growing the number and density of stem cells within a specific blood sample and seeks to enhance umbilical cord blood donations for implants to cure blood cancer in adults. Currently, umbilical cord blood can … Novartis In Advanced Talks to Acquire Israeli Stem Cell Developer Gamida-CellJewish Business News Gamida Cell Weighs Buyout; Novartis Mum on ReportGenetic Engineering News Report: Novartis circles a deal to buy Gamida Cell in $600M dealFierceBiotech Chicago Tribune (blog) all 16 news articles |
